Cardinal Health raises FY25 EPS guidance to $7.85-$8

Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...
Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...
Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...
Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...
Cardinal Health Inc. closed 2.50% below its 52-week high of $131.00, which the company reached on January 27th.
Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...
Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.